Canine Studies to Restore Endogenous Insulin

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$277,416.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK079434-01A2
Award Id:
93688
Agency Tracking Number:
DK079434
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
MITOKINE BIOSCIENCE, LLC, PO Box 275, HANCOCK, ME, 04640
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
785834164
Principal Investigator:
BLIGON
(207) 422-6838
BLIGON@MITOKINE.COM
Business Contact:
BLIGON
() -
bligon@mitokine.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Identifying a safe, oral treatment capable of both restoring the natural mechanisms that regenerate pancreatic beta cells and improving function would be a major advance in therapeutic options for diabetes. The objecti ve of the proposed research is to test the hypothesis that oral administration of a natural beta cell product, that has been depleted by the disease, will result in improved beta cell function as measured by Cpeptide, fasting glucose, glycosylated hemoglo bin and fructosamine. Twelve companion dogs that are naturally insulin-dependent will be studied in collaboration with the Clinical Sciences Department at Purdue University School of Veterinary Medicine. The aims of this research are 1) to test the feasi bility and safety of this new diabetes therapy by measuring glycemic control before and after treatment and 2) test the pharmacokinetics of the treatment at various dosages. The long-term goal is to provide an oral product for both veterinary and human dia betes that offers sustained resolution of blood glucose abnormalities by restoring endogenous insulin without side effects or toxicity. PUBLIC HEALTH RELEVANCE: The proposed research will test the hypothesis that restoring a natural product of the cell s that make insulin will improve their function and the symptoms of diabetes. The project will assess whether this treatment offers sustained improvement in glucose control without side effects or toxicity. If proven safe and effective, this treatment coul d be a major advance forward in therapeutic interventions for both type 1 and type 2 diabetes.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government